Antineoplastic AgentsRadiation InjuriesAntineoplastic Combined Chemotherapy ProtocolsRadiation DosageRadiation, IonizingDose-Response Relationship, RadiationCombined Modality TherapyRadiation ToleranceRadiotherapyRadiotherapy DosageChemotherapy, AdjuvantNeoplasmsDoxorubicinRadiationCisplatinCell Line, TumorDrug Screening Assays, AntitumorRadiation OncologyRadiation ProtectionRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRadiation MonitoringTreatment OutcomeRadiotherapy, AdjuvantDose FractionationDrug Resistance, NeoplasmApoptosisBreast NeoplasmsAntineoplastic Agents, PhytogenicRadiation PneumonitisRadiotherapy Planning, Computer-AssistedEtoposideBrachytherapyRadiation-Sensitizing AgentsAntibiotics, AntineoplasticCell SurvivalPaclitaxelNeoplasm StagingNeoplasm Recurrence, LocalBrain NeoplasmsLung NeoplasmsRadiometryDisease-Free SurvivalNeoplasms, Radiation-InducedSurvival AnalysisGamma RaysCyclophosphamideRadiation Injuries, ExperimentalDrug Delivery SystemsRadiosurgeryXenograft Model Antitumor AssaysTumor Cells, CulturedTime FactorsMice, NudeSurvival RateCranial IrradiationHead and Neck NeoplasmsPrognosisAdenocarcinomaCosmic RadiationCamptothecinDNA DamageVinblastineDrug CarriersRadiotherapy, Computer-AssistedDose-Response Relationship, DrugAntimetabolites, AntineoplasticCarcinoma, Squamous CellNeoadjuvant TherapyBleomycinCell ProliferationAntineoplastic Agents, AlkylatingParticle AcceleratorsRadiation-Protective AgentsCarboplatinRadiotherapy, Image-GuidedDrug Administration ScheduleOrganoplatinum CompoundsFollow-Up StudiesProstatic NeoplasmsRadiotherapy, High-EnergyRadiodermatitisMethotrexateEllipticinesBackground RadiationDrug Resistance, MultipleChemoradiotherapyP-GlycoproteinDacarbazineFluorouracilTumor BurdenCarcinoma, Non-Small-Cell LungClinical Trials as TopicUltraviolet RaysMitomycinDeoxycytidineInhibitory Concentration 50TaxoidsCell CycleDrug Synergism